LendingTree is compensated by companies on this site and this compensation may impact how and where offers appear on this site (such as the order). LendingTree does not include all lenders, savings ...

Following an end-of-Phase II meeting with the FDA in the fourth quarter, Viking Therapeutics plans to push its subcutaneous obesity therapy VK2735 into late-stage development and to start a Phase II ...

Viking Therapeutics VKTX is set to report third-quarter earnings on Oct. 23, after market close. Since the company lacks a marketed drug in its portfolio, we do not expect it to record revenues ...